The global Liquid Biopsy Market is expected to reach US$ 3,535.1 Mn in value by the end of 2027.


Liquid Biopsy Market

Liquid biopsy is a sophisticated cancer diagnostic technique that detects cancer using biofluids such as blood, cerebrospinal fluid (CSF), plasma, and urine. This non-invasive cancer diagnostic test employs circulating nucleic acids, circulating tumor cells (CTC), and exosomes as biomarkers.

Drivers of the Global Liquid Biopsy Market

The rising cancer prevalence is a major factor driving growth in the worldwide Liquid Biopsy Market over the predicted period. According to the World Health Organization, around 18.1 million new cases of cancer and 9.6 million deaths were recorded globally in 2018.

Furthermore, increased funding for cancer R&D is projected to boost market growth. For example, the National Cancer Research Institute (NCRI) provides cancer research funding.

Restraints in the Global Liquid Biopsy Market

Circulating free DNA (cfDNA) levels in serum and plasma differ. Such variations in cfDNA levels among patients may result in erroneous or unsatisfactory liquid biopsy test findings, limiting the global liquid biopsy market's growth.

Furthermore, the market's expansion is projected to be hampered by the high cost of Liquid Biopsy Market. The cost of equipment and reagents, as well as labour and professional expenditures, are all expenses related with liquid biopsy.

To preserve their market supremacy in ventilators, major players are producing technologically advanced goods.

Some of the main players in the global ventilators market are Becton, Philips Healthcare, ResMed Inc., Medtronic Plc, Draggers Group, Smiths Group Plc, Hamilton Medical, GE Healthcare, and Teleflex Incorporated. Market participants are working on releasing novel goods in order to preserve their competitive advantage in the ventilator business. Smiths Medical's PNEPAC para PAC medical ventilator, for example, was recently approved by the US FDA in 2014 and offers enhanced control of breathing settings as well as MRI compatibility, providing for maximum flexibility in travel within the medical setting. Manufacturers retain their competitiveness through strategies such as mergers and acquisitions with local and international enterprises, as well as an emphasis on technological advancements.

Comments